To date, approximately 30 gene mutations have been identified affecting prognosis in AML, the most important being: FMS-like tyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1), DNA methyltransferase 3A (DNMT3A), tumour protein 53 (TP53), TET methylcytosine dioxygenase 2 (TET2) and isocitrate dehydrogenase (IDH1/2) [3]. Here, FLT3 is linked to acute myeloid leukemia.